focus trial semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5 - Kushner - 2020 - Obesity Long-term weight loss effects of

As no pregnancy or lactation data exist for retatrutide, women who are breastfeeding should not use it

GLP-1 Agonists: A New Frontier in Weight Loss Drugs GLP-1 agonists represent a novel approach to addressing obesity

Reversing established pathological remodeling to treat symptomatic HF remains a critical unmet therapeutic challenge

Both are bulk-forming fiber supplements used to improve bowel regularity and relieve occasional constipation

Also showed significant reductions in liver fat (up to 82.4%) and improvements in metabolic parameters Phase 3 (TRIUMPH-4) : The Phase 3 TRIUMPH-4 trial confirmed and exceeded Phase 2 results, demonstrating 28.7% mean weight loss at 68 weeks with the 12 mg dose -- the highest reported for any metabolic peptide in a Phase 3 trial Phase 3 program : Additional Phase 3 trials ongoing for obesity (TRIUMPH-1) and type 2 diabetes (TRANSCEND) MASLD/MASH : Specific trials underway evaluating liver-related endpoints Phase 3 TRIUMPH-4 data have confirmed the Phase 2 promise, though the full Phase 3 program across all indications is still ongoing